Skip to main content
SpringerLink
Log in

Orlistat and Sibutramine in the Management of Obesity

  • Chapter
Overweight and the Metabolic Syndrome

Part of the book series: Endocrine Updates ((ENDO,volume 26))

  • 839 Accesses

9. Summary

Obesity is a chronic medical disease that is not going away any time soon. Physicians need all the education, tools, and resources possible to successfully help the overweight and obese patients in their practices. Weight loss medications alone are clearly not the answer. They represent, however, one evidencebased tool physicians can use in combination with lifestyle changes to increase long-term weight loss success in appropriate patients. Multiple studies have shown more patients can achieve a significant weight loss when they combine lifestyle and weight loss medications than either alone. Both sibutramine and orlistat have demonstrated effectiveness for obesity treatment and represent evidence-based tools physicians should consider using in appropriate patients. In the future, using combinations of weight loss medications along with new drugs in development may yield additional safe and long-term treatments to treat this serious metabolic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the Evidence Report. Obes Res 1998;6(Suppl 2):51S–210S.

    Google Scholar 

  2. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002;288:1723–1727.

    Article  PubMed  Google Scholar 

  3. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.

    Article  Google Scholar 

  4. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: A five-year perspective. Int J Obes 1989;13(Suppl 2):39–46.

    PubMed  Google Scholar 

  5. Wadden TA. Treatment of obesity by moderate and severe caloric restriction in weight loss and control: Results of clinical research trials. Ann Intern Med 1993; 119:688–693.

    PubMed  CAS  Google Scholar 

  6. Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: Patterns of weight regain among men and women. Int J Obes 1989;13:123–136.

    PubMed  CAS  Google Scholar 

  7. Skunkard AJ, McLaren-Hume M. The results of treatment for obesity. Arch Int Med 1959; 103:79–85.

    Google Scholar 

  8. Pavlou KN, Krey S, Steffee WP. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr 1989;49:1115–1123.

    PubMed  CAS  Google Scholar 

  9. Perri MG, McAllister DA, Gange JJ, Jordan RC, McAdoo WG, Nezu AM. Effects of four maintenance programs on the long-term management of obesity. J Consult Clin Psychol 1988;56(4):529–534.

    Article  PubMed  CAS  Google Scholar 

  10. Calle EE, Thum MJ, Petrelli JM, et al. Body mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999;341:1097–1105.

    Article  PubMed  CAS  Google Scholar 

  11. Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990;132:501.

    PubMed  CAS  Google Scholar 

  12. Manson JE, Willet WC, Stampfer MJ, et al. Body weight and mortality among women. N Eng J Med 1995;333:677–685.

    Article  CAS  Google Scholar 

  13. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: A systematic review. Arch Intern Med 2004;164(9):994–1003.

    Article  PubMed  CAS  Google Scholar 

  14. Bray GA. Uses and misuses of the new pharmacotherapy of obesity [editorial]. Ann Med 1999;31:1–3.

    PubMed  CAS  Google Scholar 

  15. Connolly HM, Crary J, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581–588.

    Article  PubMed  CAS  Google Scholar 

  16. Yanovski SZ, Yankovski JA. Obesity. N Engl J Med 2002;346:591–602.

    Article  PubMed  CAS  Google Scholar 

  17. Bray GA, Greenway FL. Current and potential drugs for the treatment of obesity. Endocrinol Rev 1999;20:805–875.

    Article  CAS  Google Scholar 

  18. Bray GA. Drug treatment of obesity. Psychiatr Clin N Am 2005;28:193–217.

    Article  Google Scholar 

  19. World Health Organization. Obesity: Preventing and managing the global epidemic. WHO Technical Report Series 894. Albany, NY: World Health Organization, 2000.

    Google Scholar 

  20. Peters JC, Wyatt HR, Donahoo WT, Hill JO. From instinct to intellect: The challenge of maintaining healthy weight in the modern world. Obes Rev 2002;3:69–74.

    Article  PubMed  CAS  Google Scholar 

  21. Comuzzie AG, Allison DB. The search for human obesity genes. Science 1998;280:1374–1377.

    Article  PubMed  CAS  Google Scholar 

  22. Levine JA, Eberhardt NL, Jensen MD. Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 1999;283:212–214.

    Article  PubMed  CAS  Google Scholar 

  23. Foster GD, Wadden TA, Vogt RA. What is a reasonable weight loss? Patients’ expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997;65:79–85.

    Article  PubMed  CAS  Google Scholar 

  24. Kushner RF. Roadmaps for Clinical Practice: Case Studies in Disease Prevention and Health Promotion—Assessment and Management of Adult Obesity: A Primer for Physicians. Chicago: American Medical Association, 2003.

    Google Scholar 

  25. Bray GA. Barriers to the treatment of obesity. Ann Intern Med 1991;115:152–153.

    PubMed  CAS  Google Scholar 

  26. Wyatt HR, Hill JO. What role for weight-loss medication? Weighing the pros and cons for obese patients. Postgrad Med 2004;115(1):38–40, 43–35, 58.

    Article  PubMed  Google Scholar 

  27. Downey M. Insurance coverage for obesity treatments. In: Bessesen DH, Kushner R, eds. Evaluation and Management of Obesity. Philadelphia, PA: Hanley & Belfus, 2002.

    Google Scholar 

  28. Ryan DH. Use of sibutramine to treat obesity. Prim Care Clin Office Pract 2003;30:405–426.

    Article  Google Scholar 

  29. Hollander P. Orlistat in the treatment of obesity. Prim Care Clin Office Pract 2003;30:427–440.

    Article  Google Scholar 

  30. Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment of obesity. Anna Intern Med 2005;142(7):532–546.

    CAS  Google Scholar 

  31. Wadden TA, Berkowitz RI, Sarwer DB, et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial. Arch Intern Med 2001;161(2):218–227.

    Article  PubMed  CAS  Google Scholar 

  32. Kelly F, Jones SP, Lee IK. Sibutramine; weight loss in depressed patients [abstract]. Int J Obes Related Metab Dis 1995;19(Suppl 2):145.

    Google Scholar 

  33. Luque CA, Rey JA. Sibutramine: A serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999;33:968–978.

    Article  PubMed  CAS  Google Scholar 

  34. Chapelot D, Marmonier C, Thomas F, et al. Modalities of the food intake-reducing effect of sibutramine in humans. Physiol Behav 2000;68(3):299–308.

    Article  PubMed  CAS  Google Scholar 

  35. Rolls BJ, Shide DJ, Thorwart ML, et al. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998;6(1):1–11.

    PubMed  CAS  Google Scholar 

  36. Heal DJ, Aspley S, Prow MR, et al. Sibutramine: A novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998;22(Suppl 1):S18–S28; discussion S29.

    PubMed  CAS  Google Scholar 

  37. Connoley IP, Liu YL, Frost I, et al. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 1999;126(6):1487–1495.

    Article  PubMed  CAS  Google Scholar 

  38. Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 1999;23(10):1009–1015.

    Article  PubMed  CAS  Google Scholar 

  39. Hansen DL, Toubro S, Stock MJ, et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68(6):1180–1186.

    PubMed  CAS  Google Scholar 

  40. Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998;6:115–121.

    PubMed  CAS  Google Scholar 

  41. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7(2) 189–198.

    PubMed  CAS  Google Scholar 

  42. Bray GA, Ryan DH, Gordon D, et al. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4(3):263–270.

    PubMed  CAS  Google Scholar 

  43. Dujovne CA, Zavoral JH, Rowe E, et al. Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001;142(3):489–497.

    Article  PubMed  CAS  Google Scholar 

  44. Fanghanel G, Cortinas L, Sanchez-Reyes L, et al. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord 2000;24(2):144–150.

    Article  PubMed  CAS  Google Scholar 

  45. Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000;2(2):105–112.

    Article  PubMed  CAS  Google Scholar 

  46. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebocontrolled, multicenter trial. Arch Intern Med 2000;160(14):2185–2191.

    Article  PubMed  CAS  Google Scholar 

  47. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26(1):125–131.

    PubMed  CAS  Google Scholar 

  48. Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106(2):179–184.

    Article  PubMed  CAS  Google Scholar 

  49. Cuellar GE, Ruiz AM, Monsalve MC, et al. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a hispanic population. Obes Res 2000;8(1):71–82.

    PubMed  CAS  Google Scholar 

  50. Philip W, James T, Astrup A, et al. Effect of sibutramine on weight maintenance after weight loss: A randomized trial. Lancet 2000;356(9248):2119–2125.

    Article  Google Scholar 

  51. Vettor R, Serra R, Fabris R, et al. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: A meta-analysis of clinical studies. Diabetes Care 2005;28(4):942–949.

    PubMed  CAS  Google Scholar 

  52. Wirth A, Krause J. Long-term weight loss with sibutramine: A randomized controlled trial. JAMA 2001;286(11):1331–1339.

    Article  PubMed  CAS  Google Scholar 

  53. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. Storm study group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000;356(9248):2119–2125.

    Article  PubMed  CAS  Google Scholar 

  54. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2(3):175–187.

    Article  PubMed  CAS  Google Scholar 

  55. Gokcel A, Karakose H, Ertorer EM, et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001;24(11):1957–1960.

    PubMed  CAS  Google Scholar 

  56. Serrano-Rios M, Melchionda N, Morenao-Carretero E. Spanish investigators. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulfonylurea therapy. Diabet Med 2002;19:119–124.

    Article  PubMed  CAS  Google Scholar 

  57. O’Meara S, Riemsma R, Shirran L, et al. The clinical effectiveness and cost effectiveness of sibutramine in the management of obesity. Health Technol Assess 2002;6:1–97.

    PubMed  CAS  Google Scholar 

  58. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: A metaanalysis of clinical studies. Diabetes Care 2005;28:942–949.

    PubMed  CAS  Google Scholar 

  59. Samsa GP, Kolotkin RL, Williams GR, et al. Effect of moderate weight loss on healthrelated quality of life: An analysis of combined data from 4 randomized trials of sibutramine vs placebo. Am J Manag Care 2001;7(9):875–883.

    PubMed  CAS  Google Scholar 

  60. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999;7(4):363–369.

    PubMed  CAS  Google Scholar 

  61. Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002;144(3):508–515.

    Article  PubMed  CAS  Google Scholar 

  62. Cole JO, Levin A, Beake B, et al. Sibutramine: A new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998; 18(3):231–236.

    Article  PubMed  CAS  Google Scholar 

  63. Lean ME. Sibutramine—a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21(Suppl 1):S30–S36; discussion 37–39.

    PubMed  CAS  Google Scholar 

  64. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: Evidence from placebo-controlled trials. Int J Obes 2005;29:509–516.

    CAS  Google Scholar 

  65. Narkiewicz K. Sibutramine and its cardiovascular profile. Int J Obes Relat Metab Disord 2002;26(Suppl 4):S38–S41.

    Article  PubMed  CAS  Google Scholar 

  66. Klein S. Long-term pharmacotherapy for obesity. Obes Res 2004;12(Suppl):163S–166S.

    PubMed  CAS  Google Scholar 

  67. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50(6):505–512.

    PubMed  CAS  Google Scholar 

  68. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA 1999;281(3):235–242.

    Article  PubMed  CAS  Google Scholar 

  69. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18–0647), a lipase inhibitor, in the treatment of human obesity: Multiple dose study. Int J Obes Relat Metab Disord 1995;19:221–226.

    PubMed  CAS  Google Scholar 

  70. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month dose-ranging study. Orlistat dose-ranging study group. Eur J Clin Pharmacol 1998;54(2):125–132.

    Article  PubMed  Google Scholar 

  71. Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European orlistat obesity study group. Obes Res 2000;8(1):49–61.

    PubMed  CAS  Google Scholar 

  72. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European multicentre orlistat study group. Lancet 1998;352(9123):167–172.

    Article  PubMed  CAS  Google Scholar 

  73. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: A randomized, double blinded placebo-controlled, multicenter study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Metab Disord 2000;24:306–313.

    Article  CAS  Google Scholar 

  74. Hauptman J, Lucas C, Boldrin MN, Collins HG, Seagal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160–167.

    Article  PubMed  CAS  Google Scholar 

  75. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XEN-DOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–161.

    PubMed  CAS  Google Scholar 

  76. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21(8):1288–1294.

    PubMed  CAS  Google Scholar 

  77. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25(7):1123–1128.

    PubMed  CAS  Google Scholar 

  78. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002;25(6):1033–1041.

    PubMed  CAS  Google Scholar 

  79. Ruof J, Golay A, Berne C, et al. Orlistat in responding obese type 2 diabetic patients: Meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes Relat Metab Disord 2005;29(5):517–523.

    CAS  Google Scholar 

  80. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21(Suppl 3):S12–S23.

    PubMed  CAS  Google Scholar 

  81. Drent ML, van der Veen EA. Lipase inhibition; a novel concept in the treatment of obesity. Int J Obes 1993;17:241–244.

    CAS  Google Scholar 

  82. Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996;36(11):1006–1011.

    PubMed  CAS  Google Scholar 

  83. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the doseresponse (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56(1):82–85.

    Article  PubMed  CAS  Google Scholar 

  84. Hill JO, Hauptmann J, Andersen JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1 year study. Am J Clin Nutr 1999;69:1108–1116.

    PubMed  CAS  Google Scholar 

  85. Heymsfield S, Segal K, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression of type 2 diabetes in obese adults. Arch Intern Med 2000; 160:1321–1326.

    Article  PubMed  CAS  Google Scholar 

  86. Mittendorfer B, Ostlund RE Jr, Patterson BW, et al. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001;9(10):599–604.

    Article  PubMed  CAS  Google Scholar 

  87. Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996;36(2):152–159.

    PubMed  CAS  Google Scholar 

  88. Coleman E, Fossler M. Reduction in blood cyclosporine concentrations by orlistat. N Engl J Med 2000;342:1141–1142.

    Article  Google Scholar 

  89. LeBeller C, Bezie Y, Chabatte C, Guillemain R, Amrein C, Billaud EM. Co-administration of orlistat and cyclosporin in heart transplant recipient. Transplantation. 2000; 70:1541–1542.

    Article  CAS  Google Scholar 

  90. Schnetzler B, Kondo-OeWeber C, et al. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive agents in healthy volunteers. Eur J Clin Parmacol 1996;51:87–90.

    Article  Google Scholar 

  91. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a singledose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996;36:352–355.

    PubMed  CAS  Google Scholar 

  92. Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Parmacol 1996;36:659–666.

    CAS  Google Scholar 

  93. Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995;35:840–843.

    PubMed  CAS  Google Scholar 

  94. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996;36:654–658.

    PubMed  CAS  Google Scholar 

  95. Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J. Clin Pharmacol 1995;35:521–525.

    PubMed  CAS  Google Scholar 

  96. Hartman D, Guzelhan C, Zuiderwijk PMB, Odink J. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996;50:421–424.

    Article  Google Scholar 

  97. Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: A randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005; 90(3):1460–1465.

    Article  PubMed  CAS  Google Scholar 

  98. Berkowitz RI, Wadden TA, Tershakovec AM, et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: A randomized controlled trial. JAMA 2003;289(14):1805–1812.

    Article  PubMed  CAS  Google Scholar 

  99. Chanoine JP, Hamptl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: A randomized controlled trial. JAMA 2005; 293(23):2873–2883.

    Article  PubMed  CAS  Google Scholar 

  100. Wadden TA, Berkowitz RI, Womble LG, et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo controlled trail. Obes Res 2000;8(6):431–437.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Colorado at Denver and Health Sciences Center, Denver, CO, 80262, USA

    Holly Wyatt

Authors
  1. Holly Wyatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Road, Baton Rouge, LA, USA

    George A. Bray MD  & Donna H. Ryan MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Wyatt, H. (2006). Orlistat and Sibutramine in the Management of Obesity. In: Bray, G.A., Ryan, D.H. (eds) Overweight and the Metabolic Syndrome. Endocrine Updates, vol 26. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-32164-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-32164-6_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-32163-9

  • Online ISBN: 978-0-387-32164-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation